Literature DB >> 16834944

Metastatic bone cancer pain: etiology and treatment options.

Gary C O'Toole1, Patrick Boland.   

Abstract

Painful metastatic bone disease remains a challenge for physicians. The treatment choices available are wide and varied, with each having its appropriate place in the management of painful bone metastases. Radiotherapy remains the mainstay of treatment with or without surgery. Advances in understanding the intricate pathway responsible for pain generation and the addition of agents such as bisphosphonates to the physician's armamentarium further assist in the management of painful bone metastases.

Entities:  

Mesh:

Year:  2006        PMID: 16834944     DOI: 10.1007/s11916-006-0034-y

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  39 in total

Review 1.  Bone cancer pain and the role of RANKL/OPG.

Authors:  D R Clohisy; P W Mantyh
Journal:  J Musculoskelet Neuronal Interact       Date:  2004-09       Impact factor: 2.041

Review 2.  Skeletal metastases in advanced prostate cancer: cell biology and therapy.

Authors:  M Koutsilieris
Journal:  Crit Rev Oncol Hematol       Date:  1995-01       Impact factor: 6.312

Review 3.  Use of bisphosphonates in cancer patients.

Authors:  J J Body; R E Coleman; M Piccart
Journal:  Cancer Treat Rev       Date:  1996-07       Impact factor: 12.111

Review 4.  Metastatic disease of the skeleton.

Authors:  J A Buckwalter; E A Brandser
Journal:  Am Fam Physician       Date:  1997-04       Impact factor: 3.292

5.  Disseminated intravascular coagulation in a patient with metastatic prostate cancer: fatal outcome following strontium-89 therapy.

Authors:  C Leong; M R McKenzie; D B Coupland; R D Gascoyne
Journal:  J Nucl Med       Date:  1994-10       Impact factor: 10.057

6.  Public attitudes toward cancer pain.

Authors:  D N Levin; C S Cleeland; R Dar
Journal:  Cancer       Date:  1985-11-01       Impact factor: 6.860

7.  American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.

Authors:  B E Hillner; J N Ingle; J R Berenson; N A Janjan; K S Albain; A Lipton; G Yee; J S Biermann; R T Chlebowski; D G Pfister
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

Review 8.  Role of endothelin-1 in osteoblastic bone metastases.

Authors:  Theresa A Guise; Juan Juan Yin; Khalid S Mohammad
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

9.  A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.

Authors:  Jean-Jacques Body; Philip Greipp; Robert E Coleman; Thierry Facon; Filip Geurs; Jean-Paul Fermand; Jean-Luc Harousseau; Allan Lipton; Xavier Mariette; Catherine D Williams; Arline Nakanishi; Donna Holloway; Steven W Martin; Colin R Dunstan; Pirow J Bekker
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

10.  Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts.

Authors:  D R Clohisy; C M Ogilvie; R J Carpenter; M L Ramnaraine
Journal:  J Orthop Res       Date:  1996-01       Impact factor: 3.494

View more
  2 in total

1.  Efficacy of percutaneous vertebroplasty for the relief of osteoblastic spinal metastasis pain.

Authors:  Songfeng Xu; Ting Liu; Xinxin Zhang; Huanmei Liu; Zhenguo Zhao; Libin Xu; Shengji Yu
Journal:  Exp Ther Med       Date:  2021-05-04       Impact factor: 2.447

2.  The nociceptin/orphanin FQ receptor system as a target to alleviate cancer-induced bone pain in rats: Model validation and pharmacological evaluation.

Authors:  Sonny H J Sliepen; Johanna Korioth; Thomas Christoph; Thomas M Tzschentke; Marta Diaz-delCastillo; Anne-Marie Heegaard; Kris Rutten
Journal:  Br J Pharmacol       Date:  2020-01-21       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.